Taho Pharmaceuticals Ltd. (6467)

Overview

Taho Pharmaceuticals Ltd. is a Taiwan-based pharmaceutical company that specializes in innovative drug delivery technologies. Established in 2010 and headquartered in Taipei, the company focuses primarily on transdermal patches and transmucosal oral dissolving films. Taho aims to enhance both the clinical performance and accessibility of established pharmaceutical compounds by reengineering them into novel dosage forms. This reengineering seeks to improve patient compliance, safety, and therapeutic efficacy. Utilizing proprietary platforms such as the Transepithelial Delivery System, Taho enables drug delivery through the skin or mucosal membranes, resulting in benefits such as consistent plasma levels and reduced risk of choking—an aspect particularly advantageous for populations with difficulty swallowing. The company's development pipeline includes targets for central nervous system, geriatric, and pediatric disorders, which reflects its commitment to addressing unmet medical needs on both regional and global scales.

Products and Services

• Transdermal Patches

  Taho's transdermal patches are designed to deliver medication effectively through the skin. These patches not only facilitate continuous drug absorption, ensuring stable plasma levels, but also enhance patient compliance by providing an alternative route of administration that is easier for many patients to manage.

• Transmucosal Oral Dissolving Films

  The company's oral dissolving films allow for rapid absorption of medication through the mucosal membranes inside the mouth. This form of drug delivery is beneficial for patients who experience difficulties swallowing tablets or capsules, thereby improving the accessibility of essential medications for such populations.

• Transepithelial Delivery System

  Taho's proprietary Transepithelial Delivery System is a cutting-edge technology that enhances drug delivery through skin and mucosal barriers. By optimizing the permeability and absorption rates, this system allows for a more effective therapy for various medical conditions without the associated risks of traditional delivery methods.

• Central Nervous System Products

  This category includes products targeting disorders such as ADHD and epilepsy. Taho is focused on creating innovative delivery methods that improve the therapeutic results and patient usability of medications intended to manage these conditions.

• Geriatric and Pediatric Treatments

  Taho also emphasizes the development of products specifically for geriatric and pediatric populations. These products take into account the unique needs and challenges of these groups, ensuring that medications are both safe and effective when administered to older adults and children.

• Chemotherapy-Induced Nausea Solutions

  In addressing the side effects of chemotherapy, Taho provides innovative formulations aimed at alleviating nausea. These solutions are crucial for improving the quality of life in patients undergoing cancer treatment.

• Anticoagulation Therapy

  With an emphasis on safety and efficacy, Taho's offerings in anticoagulation therapy are designed to provide consistent therapeutic effects, potentially minimizing the risks of complications associated with traditional anticoagulants.

• Opioid Addiction Treatments

  Recognizing the ongoing opioid crisis, Taho is engaged in developing therapies that address opioid addiction, aiming to contribute to the broader fight against this public health issue through innovative drug delivery systems.